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EDITORIAL

Eradicating the Viral Triad in Hemodialysis
Units

I

n this issue of Advances in Chronic Kidney Diseases, Dr
James Novak as Guest Editor has curated a collection
of manuscripts from a cadre of nephrologists whose curiosity includes the viral nephropathies. The authors
present a well-researched group of articles that comprehensively review the vast majority of contemporary viral
disorders with which most nephrologists will engage at
some point in their careers. However, the bulk of nephrologists will be concerned with 3 viruses more than others,
hepatitis C virus (HCV), hepatitis B virus (HBV), and the
human immunodeﬁciency virus-1 (HIV).
Adenovirus,1 cytomegalovirus,2 Epstein-Barr virus,3
Hantavirus,4 hepatitis A virus,5,6 HIV,7 inﬂuenza,8 polyoma virus (eg, BK virus),9 and parvovirus B19 virus (Fifth
disease)10 among others reproduce in renal parenchyma.
These vectors rarely cause acute and/or chronic tubulointerstitial nephritis, considering their prevalences. These
infections are frequently indolent, escaping detection until
signiﬁcant kidney tissue has been lost.
This group of viral nephropathies will generally not
come under the purview of primary care physicians.
However, primary care physicians may chance on these
patients as ﬁrst responders. Therefore, education
regarding the potential signs and symptoms of viral nephropathies should be disseminated. The presence of
new onset hematuria, leukocyturia, and dipstick albuminuria is widely variable, but even 1 sign is enough to warrant referral to a nephrologist, particularly if there is an
increase in the serum creatinine concentration. When
these viral nephropathies are engaged by nephrologists,
the clinical scenario is often one of intentional immunosuppressions as might occur in a kidney transplant recipient. Essentially, a dormant infection, afﬁanced to its host,
is granted license to reawaken and does. Rapid recognition of reactivated virus and reduction of immunosuppression is renal-sparing.
Viral nephropathies that produce glomerulonephritis
are confronted by primary care physicians and nephrologists, with cardinal features of hematuria and proteinuria.
However, the non-nephrologist more often encounters the
viral triad of HCV, HBV, and HIV as a nonrenal disorder.

When kidney disease is recognized, infection has usually
been long established. For practicing nephrologists, this
virologic triad has produced vexation, requiring exasperating effort just to maintain prevalence levels at status
quo. Ebola won the prize for intensity of effort, but that intensity was short-lived compared with the eradication efforts devoted to HCV, HBV, and HIV.
One-third of the triad, HIV, can now be contained by
highly active antiretroviral therapy (HAART), which
saves lives and precludes kidney disease. Patient adherence to HAART is now the most important aspect of therapy, not the agents. To this point, in 2 longitudinal,
prospective, observational HIV studies of men and
women, Multicenter Acquired Immunodeﬁciency Syndrome (AIDS) Cohort Study and Women’s Interagency
HIV Study, only one-third of 198 participants were on
an HAART regimen that did not include nephrotoxic tenofovir disoproxil fumarate.11 Currently, because of the
success of HAART, HIV treatment is mostly out of nephrologists’ hands now. Likely, the most crucial knowledge for the nephrologists may be recognition of agents
that require renal-dosing adjustments. An excellent source
for this expertly compiled information may be found at
the University of California, San Francisco Web site.12
Although the prevalence of HIV in hemodialysis (HD)
in-centers may be relatively increased in some urban
areas, viral transmissibility is not an overwhelming
concern as it is for HBV and HCV. These 2 viruses may
induce indirectly glomerular and tubulointerstitial
compartmental damage via circulating immune complexes, cryoglobulins, and cytokines. Hepatitis B, the second member of the viral triad, is now rare in HD units,
and its prevalence could be reduced to nearly zero in nonendemic areas if hepatitis B surface antigen-positive patients received treatment with lamivudine13 or the more
potent entecavir,14 if surveillance for surface antigen
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positivity is conducted on an ongoing basis unit-wide.
Treatment of HBV-infected ESRD patients treated with
HD offers results equivalent to HBV-infected persons
not on HD.13 The probability of success may be increased
if treatment plans are conducted in parallel with a dedicated immunization program. However, the true rates of
immunization of patients with CKD against HBV are unknown. CKD clinics are rarely equipped to vaccinate patients across the entire vaccine palette proposed for
them. The foci of greatest immunization intent have
been inﬂuenza viruses and the pneumococcus, and justiﬁably so.
Inﬂuenza vaccination rates in patients on dialysis
remain suboptimal at just 60%.15 Immune responsiveness
is impaired, although this “truism” has been challenged
recently.16 Recently, a small trial demonstrated that
booster immunization may provide vaccine efﬁcacy equal
to control subjects.17 Validation of this study would be a
game-changer, if the correct inﬂuenza strain could be reliably predicted. In fact, reports of vaccine efﬁcacy are sullied by the imprecision of attributing vaccine failure to the
use of the “wrong” vaccine, which is akin to tackling the
wrong man in a game of football. The overall incidence
rate for pneumonia was reported at 27.9 per 100 patientyears (29.0 in patients on HD vs 18.2 in patients on peritoneal dialysis, P , .0001) and was nearly constant from
1996 to 2001.18 Interestingly, in a more recent Taiwanese
study, the incidence density rate of pneumonia was 65.6
per 1000 person-years in patients with CKD and 28.4
per 1000 person-years in individuals without CKD. Pneumonias in patients with ESRD persist and portend cardiovascular disease and death.19
Despite that CKD is prevalent in the United States, the
Advisory Committee for Immunization Practice (Centers
for Disease Control, Atlanta) has not issued a special
call for immunization of patients with CKD Stage 4
when the immune response to recombinant HBV is far
better than when individuals are immunized after initiation of renal replacement therapy. When the switch from
a more vigorous immune response to one suboptimal is
not known precisely, consequently, it might prove better
to immunize all patients with CKD Stage 4 at a predetermined estimated glomerular ﬁltration rate. And, would
that be cost-effective? Only a well-designed study could
prove this hypothesis. If proven, implementation would
be difﬁcult as knowing when a patient crosses the
threshold for immunization requires repetitive serum
creatinine–based testing to determine the glomerular
ﬁltration rate. Perhaps the recently available toll-like receptor 9-adjuvanted 2-dose injection series for HBV (He€ sseldorf)20 will be more greatly
plisav-B; Dynavax, Du
adhered to than the currently prescribed 3-dose 40-mg injection series (Recombivax HB Dialysis Formulation;
Merck & Co, White House Station).21
No matter which vaccine is stocked in one’s CKD clinic
and intends to administer, my advice is to employ motivational interviewing in early CKD Stage 4 for immunization of all recommended vaccines. Such practice would
additionally ensure that vulnerable patients receive an
HBV vaccine, the 13- and 23-valent pneumococcal poly-

saccharide immunizations, and annual inﬂuenza vaccinations. If stockage of these vaccines is not possible in one’s
practice, then urgency of discussion with and education of
primary care providers is required because these health
care providers must embrace the responsibility of protecting the patients against these pathogens. Irrespective of
the aforementioned, patients who are at risk for progression to CKD Stage 5 must be vaccinated against HBV,
inﬂuenza, and pneumococcus.
HCV, the third member of the triad, is now the greatest
nonbacterial threat for in-center HD units. HCV represents a risk for patient and provider. Now, HCV is
eminently treatable. Unlike before, there is high tolerability of direct-acting antiviral (DAA) therapy-based regimens, per a recent meta-analysis22: ,10% of patients in
the 42 clinical trials analyzed withdrew from therapy. Efﬁcacy as delineated by 8-week sustained virologic
response rates against genotype 1 HCV was .95% for
the 6 major DAA studies analyzed for this result.
Response rates were 78% to 85% in patients with hepatic
decompensation. Many patients enter the dialysis population with known HCV seropositivity and some degree of
chronic liver disease. As per the international Dialysis
Outcomes and Practice Pattern Study, the prevalence of
HCV among patients on maintenance dialysis in the
United States is 8.6%,23 5-fold greater than the general
population. Part of the reason is that 62% of HD units
do not screen for HCV.24 Urban HD units may have a
signiﬁcantly greater prevalence of HCV seropositivity.
Seroconversion of a patient from HCV-negative to HCVpositive status is usually attributed to breaks in universal
precautions or sterilization procedures. Furthermore,
infection with HCV is a known risk factor for developing
advanced CKD and glucose intolerance through impaired
expression of insulin substrate-1. Worse yet, HCV infection with coincident HIV infection may be encountered.
Unfortunately, until recently, nephrologists have rarely
treated HCV. The management and treatment of HCV
was minimal attributable to 2 major factors, drug toxicity
and altered pharmacokinetics.25,26 Pegylated interferonrelated drug toxicity of HCV-afﬂicted HD patients in the
era preceding DAA therapy manifested as ﬂu-like syndrome, weight loss, and myelosuppression in patients
on dialysis. However, patients with ESRD actually and
somewhat paradoxically fared better than normal kidney
function patients, likely because of higher drug levels of
an antiviral agent during monotherapy with pegylated
interferon. Early treatment models using interferon monotherapy yielded sustained viral 48-week remission rates of
approximately 40% of cases. Combination therapy with
ribavirin was associated with a 50% sustained viral
response, only 10% less than seen in normal kidney function patients.26 These studies were small and underscored
the widespread fear of ribavirin-mediated hemolysis, a
fear that likely led to undertreatment of many HCVpositive patients. Hepatologists essentially did not refer
patients with HCV-induced kidney disease to nephrologists, presuming that kidney doctors would forgo therapy
for fear of hemolysis. Even had 30% of treated patients
withdrawn from therapy because of side effects, 30% to
Adv Chronic Kidney Dis. 2019;26(3):157-161
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35% of patients overall were denied the chance for cure
from HCV. With the success of DAA therapies, patientcentered approaches to treating both HCV and CKD
may be beneﬁcial, so patients and clinicians can consider
how to manage both diseases. Patient education and decision support tools may improve disease management and
adherence.27
Despite the resounding success of contemporary
HAART for HIV infections, patients coinfected with
HCV and HIV fare worse than monoinfected counterparts
in terms of advanced liver ﬁbrosis and cirrhosis.28-31
Coinfected patients also incur greater degrees of liverrelated morbidity and mortality, extrahepatic organ
dysfunction, and demonstrate an overall greater mortality
rate than HCV-monoinfected individuals.32 Therefore, nephrologists should collaboratively treat such patients with
either an infectious diseases’ subspecialist or internist
trained in HIV medicine and a hepatologist. Medication
reconciliation in this patient population is extremely
important because of differences in and interactions of
metabolic pathways used by drugs for HIV and HCV.
Notably, HBV reactivation may occur in individuals
treated with DAA therapy for HCV infection.1
Given the rarity of HBV infections in HD units and the
ability to successfully treat HIV with HAART, HCV remains the last of the viral triad to overcome. After the success of the multicenter, open-label C-Surfer trial in which
98% of CKD stages 4 and 5 with HCV, genotypes 1 to 6,
with compensated liver disease (with or without cirrhosis)
experienced a 12-week sustained viral response to therapy
comprising the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir, nephrologists were empowered to “easily” treat their HCV
cohorts.33 The rush to treat never transpired, and HCV remains more prevalent in HD units that it rightfully
should. Nephrologists are reluctant to treat for possibly
several reasons: ﬁnancial, inadequate education on how
to effect therapy, or disinclination because of lack of
mandate. None of these reasons/excuses are acceptable.
Placing HCV-coinfected patients aside for the moment,
how can HCV be effectively eradicated from HD units,
now that DAA therapy has matured to the point of pangenotypicity, with combination therapies as outlined by
the World Health Organization?34 Although multiple regimens for patients with CKD have been trialed successfully, only the combination of glecaprevir and
pibrentasvir (Mayveret; Abbvie, North Chicago) is ofﬁcially endorsed for individuals with CKD: “Data are insufﬁcient on the safety and efﬁcacy of sofosbuvir-based
regimens in persons with severe renal impairment. Glecaprevir/pibrentasvir is effective against infection with
all 6 major genotypes in persons with chronic kidney disease.”34
The elimination of HCV from in-center dialysis units is
an interdisciplinary process that is gauged toward identiﬁcation of patients with HCV and determination of the
optimal treatment pathway. Initial screening for antibody
directed against HCV is recommended by the Centers for
Disease Control and prevention on an annual basis. However, the Centers for Medicare and Medicaid Services has
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not accepted this recommendation, thereby permitting a
“no HCV screening” environment. Patients positive for
anti-HCV antibody should undergo subsequent identiﬁcation of “live” RNA virus by “reﬂex” polymerase chain
reaction testing to produce a “viral load” result. This
testing is expensive, as is the next recommended step of
genotyping. In the capitated and bundled environment
in which nephrologists working in dialysis units live,
achieving this laudable goal suddenly becomes a penurious procedure. To obviate this ﬁnancial obstacle, the
partnering of nephrology with hepatology is essential.
Ideally, the hepatologist who would ultimately review
the patient’s care and prescription of a DAA-based drug
combination would collaboratively order all necessary
laboratory tests and procedures, outside the dialysis
“bundle,” after the presence of anti-HCV antibody is
conﬁrmed and the viral load has been quantiﬁed. Genotyping can be coupled with resistance testing. Afterward,
a hepatic ﬁbrosis scan, based on transient elastography, is
a painless and rapid maneuver that can be used to quantify liver stiffness vis-a-vis cirrhosis. Alternatively,
because of the nonuniversal availability and expense of
an elastography machine, the noninvasive biomarkerderived FibroSURE test (LabCorp, Burlington) may be
substituted to produce a numerical score (,0.21 to
.0.74) that well correlates with the extent of liver damage
in persons with several non-HCV liver disorders,
including HBV, alcoholic cirrhosis, and nonalcoholic fatty
liver disease, that is, steatohepatitis.35 FibroSURE
algorithmically generates its score, which correlates with
liver biopsy, from serum levels of a2-macroglobulin,
haptoglobin, apolipoprotein A1, bilirubin, and gamma
glutamyl transpeptidase, age, and gender. Should DAA
treatment be advised after collation and interpretation
of these data, the patient is treated outside the dialysis
unit after sufﬁcient patient education and informed
consent.
In the circumstance that an HCV-positive ESRD patient
is eligible for heterotopic kidney transplantation, DAA
treatment may be delayed until after surgery. This strategy
is predicated on the probability that the recipient will live
longer with an HCV-infected and treated organ than remaining on dialysis and only undergoing DAA treatment.
A recent United States analysis via a Markov statetransition decision model examined the question of
whether it was more cost-effective to transplant HCVinfected or HCV-uninfected kidneys into HCV-infected
patients.36 The investigators concluded: “Transplant of
an HCV-infected kidney followed by HCV treatment
was more effective and less costly than transplant of an
HCV-uninfected kidney preceded by HCV treatment,
largely because of longer wait times for uninfected kidneys. A typical 57.8-year-old patient receiving HD would
gain an average of 0.50 quality-adjusted life-years (QALY,
a generic measure of disease burden), including both the
quality and the quantity of life lived at a lifetime cost savings of $41,591.” The efﬁcacy of this strategy has been long
opined by likely all of us,37 especially given the unpalatably excessive discard rate of HCV-positive kidneys.38
However, this study does lend some credence to the
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practice of delaying DAA therapy in patients with ESRD
in lieu of potentially successful orthotopic liver transplantation.
In conclusion, the viral triad of hepatitides B and C and
HIV that has produced much heartache for nephrologists
and greater sorrow for patients can be overcome with
dedicated, evidence-based, and judicious care. It is
improbable that the inﬂux of HCV, HBV, and HIV into
HD centers will stop, given the nature of their entries in
vulnerable and high-risk patients. Nonetheless, the strategies proposed offer overall reductions for these respective
virions. Implementation is as important as strategy. The
processes of care to achieve these ends require collaboration among nurses, advance practice providers, primary
care physicians, nephrologists, infectious disease and/or
hepatologists, and patients. We will have to change the
mien to change the mean.
Beth Adams, PA-C
Division of Nephrology and Hypertension
Henry Ford Hospital
Detroit, MI
Jerry Yee, MD
Editor-in-Chief
Henry Ford Hospital
Detroit, MI
Professor of Clinical Medicine
Wayne State University
Detroit, MI
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